Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Shanghai Vinnerna Biosciences Co., Ltd.

ClinicalTrials.gov lists Shanghai Vinnerna Biosciences Co., Ltd. as lead sponsor of 10 trials. It has 1 active development program and 1 approved asset.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 1 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 1 Approved assets Approved assets 1 Sponsor delivery record Sponsor delivery record 1 Journals published in Journals published in 1 Latest dated events Latest dated events 10 Biomarker capability evidence Biomarker capability evidence 10 Disease areas Disease areas 1 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Active development programs Active development programs 1 Approved assets Approved assets 1 Sponsor delivery record Sponsor delivery record 1 Journals published in Journals published in 1 Latest dated events Latest dated events 10 Biomarker capability evidence Biomarker capability evidence 10

Rows recorded per section

16 sections measured, none recorded

This page covers Shanghai Vinnerna Biosciences Co., Ltd.: 10 lead-sponsored trials and 0 legal-entity registrations.

Get the Shanghai Vinnerna Biosciences Co., Ltd. report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (1)

Disease areas
Disease area Trials
COVID-19 1

Trials by start year as sponsor or collaborator (2)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2023 6
2022 4

No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Active development programs (1)

Active development programs
Drug Disease area Max phase Trials
JT001 COVID-19 Not reported 1

Approved assets (1)

Approved assets
Drug Trials
Favipiravir 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
40% hit target (n=5) 2 of 4 on time (n=4)

Journals published in (1)

Journals published in
Journal Publications
The Lancet. Infectious diseases 1

Latest dated events (10)

Shown in this order: newest first.

Latest dated events
Date Event Source
2023-08-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-08-15 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-07-28 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-07-12 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-05-08 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 10 events.

Start your 14-day trial Email me all 10 events as a PDF

Biomarker capability evidence (10)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCG2 Trial sponsor Named in trial exclusion criteria
ABCG2 Trial sponsor Named in trial exclusion criteria
ABCG2 Trial sponsor Named in trial exclusion criteria
AFP Trial sponsor Named in trial exclusion criteria
F2 Trial sponsor Named in trial exclusion criteria

Showing 5 of 10 evidence rows.

Start your 14-day trial Email me all 10 evidence rows as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.